First Time Loading...
I

Immuneering Corp
NASDAQ:IMRX

Watchlist Manager
Immuneering Corp
NASDAQ:IMRX
Watchlist
Price: 1.6 USD 0.63% Market Closed
Updated: May 15, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Cash Flow Statement

-49m
-0.1%
Operating Cash Flow
Growth Rates:
1 Year
-11%
3 Years
-
5 Years
-
7 Years
-
10 Years
-
7.3m
-41%
Investing Cash Flow
Growth Rates:
1 Year
-83%
3 Years
-
5 Years
-
7 Years
-
10 Years
-
28.4m
+0.7%
Financing Cash Flow
Growth Rates:
1 Year
+142 105%
3 Years
-
5 Years
-
7 Years
-
10 Years
-

Cash Flow Statement
Immuneering Corp

Rotate your device to view
Cash Flow Statement
Currency: USD
Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023
Operating Cash Flow
Net Income
(20)
(24)
(33)
(34)
(40)
(44)
(48)
(51)
(51)
(52)
(52)
(53)
Depreciation & Amortization
0
0
0
0
0
0
0
0
0
0
0
0
Change in Deffered Taxes
0
0
0
(0)
0
0
0
0
0
0
0
0
Stock-Based Compensation
1
2
2
2
3
3
4
4
4
5
5
0
Other Non-Cash Items
1
1
2
2
3
4
4
4
4
5
5
5
Change in Working Capital
1
2
1
1
0
0
2
2
0
(1)
(2)
(1)
Cash from Operating Activities
(18)
N/A
(22)
-17%
(31)
-42%
(31)
-1%
(37)
-20%
(40)
-8%
(42)
-4%
(44)
-6%
(46)
-5%
(48)
-3%
(49)
-3%
(49)
0%
Investing Cash Flow
Capital Expenditures
(0)
(0)
(0)
(0)
(0)
(0)
(1)
(1)
(1)
(1)
(0)
(0)
Other Items
0
0
(53)
(76)
(63)
(41)
12
43
49
36
13
8
Cash from Investing Activities
(0)
N/A
(0)
-14%
(53)
-65 963%
(76)
-43%
(63)
+16%
(41)
+35%
11
N/A
42
+285%
48
+16%
35
-27%
12
-65%
7
-41%
Financing Cash Flow
Net Issuance of Common Stock
37
63
183
146
147
121
0
0
0
29
29
29
Other
0
0
(2)
(2)
0
0
(0)
(0)
0
(0)
(0)
(0)
Cash from Financing Activities
37
N/A
63
+70%
181
+189%
144
-20%
144
+0%
119
-18%
0
-100%
0
-90%
0
+250%
28
+40 200%
28
+0%
28
+1%
Change in Cash
Net Change in Cash
18
N/A
41
+123%
98
+138%
38
-61%
44
+17%
38
-15%
(31)
N/A
(2)
+93%
2
N/A
16
+621%
(8)
N/A
(13)
-58%
Free Cash Flow
Free Cash Flow
(19)
N/A
(22)
-17%
(31)
-42%
(31)
-1%
(37)
-20%
(40)
-8%
(42)
-5%
(45)
-6%
(47)
-5%
(48)
-3%
(49)
-2%
(49)
0%

See Also

Summary
IMRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
IMRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
IMRX stock valuation using valuation multiples.
Wall Street Estimates
IMRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
IMRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 137,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.